Literature DB >> 7493911

Low incidence of a nucleotide sequence alteration of the neurofibromatosis 2 gene in human breast cancers.

S Yaegashi1, R Sachse, N Ohuchi, S Mori, T Sekiya.   

Abstract

We investigated aberrations of the neurofibromatosis type 2 (NF2) gene in breast tumors of 60 patients by single-strand conformation polymorphism analysis of polymerase chain reaction products followed by nucleotide sequencing. We detected a tumor-specific single-base substitution in codon 398 in exon 12 of the gene, resulting in an alteration of a single amino acid, in DNA from a breast cancer sample. The results indicated possible but infrequent involvement of mutations of the tumor suppressor NF2 gene in human breast cancers.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7493911      PMCID: PMC5920597          DOI: 10.1111/j.1349-7006.1995.tb03003.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  27 in total

1.  A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; D Teare; V Newton; T Strachan; R Ramsden; R Harris
Journal:  J Med Genet       Date:  1992-12       Impact factor: 6.318

2.  Improved double-stranded DNA sequencing using the linear polymerase chain reaction.

Authors:  V Murray
Journal:  Nucleic Acids Res       Date:  1989-11-11       Impact factor: 16.971

3.  Use of labeled primers in polymerase chain reaction (LP-PCR) for a rapid detection of the product.

Authors:  K Hayashi; M Orita; Y Suzuki; T Sekiya
Journal:  Nucleic Acids Res       Date:  1989-05-11       Impact factor: 16.971

4.  Germline mutations in the neurofibromatosis type 2 tumour suppressor gene.

Authors:  D Bourn; S A Carter; S Mason; D Gareth; R Evans; T Strachan
Journal:  Hum Mol Genet       Date:  1994-05       Impact factor: 6.150

5.  Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas.

Authors:  M H Ruttledge; J Sarrazin; S Rangaratnam; C M Phelan; E Twist; P Merel; O Delattre; G Thomas; M Nordenskjöld; V P Collins
Journal:  Nat Genet       Date:  1994-02       Impact factor: 38.330

6.  A mutation in the neurofibromatosis type 2 tumor-suppressor gene, giving rise to widely different clinical phenotypes in two unrelated individuals.

Authors:  D Bourn; S A Carter; D G Evans; J Goodship; H Coakham; T Strachan
Journal:  Am J Hum Genet       Date:  1994-07       Impact factor: 11.025

7.  Exon scanning for mutation of the NF2 gene in schwannomas.

Authors:  L B Jacoby; M MacCollin; D N Louis; T Mohney; M P Rubio; K Pulaski; J A Trofatter; N Kley; B Seizinger; V Ramesh
Journal:  Hum Mol Genet       Date:  1994-03       Impact factor: 6.150

8.  Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas.

Authors:  R H Lekanne Deprez; A B Bianchi; N A Groen; B R Seizinger; A Hagemeijer; E van Drunen; D Bootsma; J W Koper; C J Avezaat; N Kley
Journal:  Am J Hum Genet       Date:  1994-06       Impact factor: 11.025

9.  Mutational analysis of patients with neurofibromatosis 2.

Authors:  M MacCollin; V Ramesh; L B Jacoby; D N Louis; M P Rubio; K Pulaski; J A Trofatter; M P Short; C Bove; R Eldridge
Journal:  Am J Hum Genet       Date:  1994-08       Impact factor: 11.025

10.  Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer.

Authors:  T Sato; A Tanigami; K Yamakawa; F Akiyama; F Kasumi; G Sakamoto; Y Nakamura
Journal:  Cancer Res       Date:  1990-11-15       Impact factor: 12.701

View more
  5 in total

1.  Loss of tumor suppressor Merlin in advanced breast cancer is due to post-translational regulation.

Authors:  K Adam Morrow; Shamik Das; Brandon J Metge; Keqiang Ye; Madhuri S Mulekar; J Allan Tucker; Rajeev S Samant; Lalita A Shevde
Journal:  J Biol Chem       Date:  2011-09-30       Impact factor: 5.157

Review 2.  Merlin: the wizard requires protein stability to function as a tumor suppressor.

Authors:  K Adam Morrow; Lalita A Shevde
Journal:  Biochim Biophys Acta       Date:  2012-06-30

Review 3.  Role of Merlin/NF2 inactivation in tumor biology.

Authors:  A M Petrilli; C Fernández-Valle
Journal:  Oncogene       Date:  2015-04-20       Impact factor: 9.867

4.  Loss of tumor suppressor Merlin results in aberrant activation of Wnt/β-catenin signaling in cancer.

Authors:  K Adam Morrow; Shamik Das; Erhong Meng; Mitchell E Menezes; Sarah K Bailey; Brandon J Metge; Donald J Buchsbaum; Rajeev S Samant; Lalita A Shevde
Journal:  Oncotarget       Date:  2016-04-05

5.  Merlin deficiency alters the redox management program in breast cancer.

Authors:  Mateus Mota; Brandon J Metge; Dominique C Hinshaw; Heba A Alsheikh; Dongquan Chen; Rajeev S Samant; Lalita A Shevde
Journal:  Mol Oncol       Date:  2021-02-01       Impact factor: 6.603

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.